Navigation Links
diaDexus, Inc. Highlights Findings from Two Outcomes Studies for its PLAC Lp-PLA(2) Activity Assay
Date:3/19/2012

duct.)

** PM Ridker et.al., Clinical Chemistry  58:5 (2012)

About the LIPID trial

The LIPID trial was a randomized controlled trial to determine the effects of cholesterol lowering on death from coronary heart disease among patients with coronary disease and average lipid levels. The trial was designed and initiated by Australian and New Zealand researchers including members of the Clinical Trials Research Unit of Auckland City Hospital, New Zealand. The trial involved 9014 patients, 3,056 of whom were recruited from New Zealand, and all of whom had a prior history of myocardial infarction or hospitalization for unstable angina. The study began in 1990 and was terminated at the end of 1997 (on the advice of the Data Monitoring Committee) as a result of evidence of a clear beneficial effect of pravastatin.

About the JUPITER trial

The JUPITER trial was a randomized, double-blind, placebo-controlled trial that investigated whether rosuvastatin 20 mg compared to placebo would decrease the rate of first major cardiovascular events. The trial enrolled 17,802 apparently healthy men and women with elevated levels of C-reactive protein. The trial was conducted by investigators in 26 countries and overseen by an academic statistician (Robert Glynn, PhD, Harvard University, USA) and an independent Data and Safety Monitoring Board (chaired by Professor Rory Collins, Oxford University, UK). The study was funded by AstraZeneca, US who had no access to unblinded trial data and played no role in analysis or interpretation of the study data or in manuscript preparation. Dr. Ridker, the JUPITER principal investigator, is listed as a co-inventor on patents held by Brigham and Women's Hospital  that relate to the use of inflammatory biomarkers in cardiovascular disease that have been licensed to AstraZeneca.

About diaDexus, Inc.

diaDexus, Inc., based in South San Francisco, California, is f
'/>"/>

SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. diaDexus, Inc. Reports 2011 Fourth Quarter and Year-End Financial Results
2. diaDexus, Inc. to Host Webcast March 15, 2012 on 2011 Fourth Quarter and Year-End Financial Results
3. diaDexus, Inc. Reports 38% Year-Over-Year Revenue Growth for 2011 Third Quarter
4. diaDexus, Inc. Reports 2011 First Quarter Financial Results
5. diaDexus, Inc. Reports 2010 Third Quarter Financial Results
6. diaDexus, Inc. Adds Two New Directors; Corporate Overview & 3Q Results Webcast Set for November 16, 2010
7. Elekta Highlights Latest Version of MOSAIQ Oncology Information System at HIMSS12 Meeting
8. Bionovo to Host Conference Call to Discuss 2011 Highlights and Year-End Financial Results
9. UBM Medicas Musculoskeletal Network Highlights Key Orthopedic Findings From AAOS
10. Zacks Voice of the People highlights opportunities with Walgreen, Occidental Petroleum and Brown & Brown
11. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ... on the development and commercialization of innovative therapies for ... the PDUFA date for Zalviso remains July 27, 2014.  ... circulated online stating the Food and Drug Administration (FDA) ... has been no notification to the company from the ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
(Date:7/24/2014)... 2014  Uroplasty, Inc. (NASDAQ: UPI ), ... markets innovative proprietary products to treat voiding dysfunctions, ... first quarter ended June 30, 2014.  Global ... System grew 19% to $4.1 million, as compared ... the prior year.  Total revenue for the fiscal ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... Pa., April 23 Wyeth,Pharmaceuticals, a division of ... it,is withdrawing its application for an extension to ... sought approval,of TYGACIL for the treatment of community-acquired ... of the Committee for Medicinal,Products for Human Use ...
... an Investigational Drug for Duchenne/Becker ... Muscular Dystrophy, ... announced the initiation of an international pivotal trial of,PTC124 in patients ... objective of this registration-directed,Phase 2b trial is to demonstrate the efficacy ...
Cached Medicine Technology:More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 2More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 3More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 4More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL 5PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 2PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 3PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 4PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 5
(Date:7/25/2014)... in the U.S. are living with a brain tumor, ... risk factors, scientists are still searching for answers. , ... when, and we don,t know why people develop brain ... American Brain Tumor Association. "It,s frustrating for the brain ... Association funds research to pursue answers to these questions, ...
(Date:7/25/2014)... CMS recently has imposed a series ... inadequate access to prescription drugs. Agency audits are uncovering ... safety of beneficiaries in areas such as rejected pharmacy ... is taking quick and firm actions to halt them. ... “Avoiding Costly Part D Sanctions: Rx Access Strategies ...
(Date:7/25/2014)... Fort Myers, FL (PRWEB) July 25, 2014 ... Apple iPhones, iPods, and iPads. The app provides a ... preventing painful and potentially dangerous sunburns and skin damage. ... about the sights, sounds, and capabilities of iTanSmart. ... by describing the app as a ‘better organized’ and ...
(Date:7/25/2014)... July 25, 2014 As the category creator ... Xoçai is to transform and improve individual lives ... Adam Paul Green a successful Austin, Texas based ... at the end of the July to promote the up ... September 2014. , Eric Worre has been a leader in ...
(Date:7/24/2014)... July 25, 2014 iFitDress.com, a renowned ... new range of casual party dresses . According ... party gowns are now offered at discounted prices, up ... this morning until August 04. , Most of ... in the global market. They are popular for special ...
Breaking Medicine News(10 mins):Health News:Brain tumor causes and risk factors elude scientists 2Health News:Aug. 5 Webinar to Offer Strategies for Preventing Rx Access Issues and Avoiding Part D Sanctions 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2
... Companies Will Discuss Recent FDA Advisory Regarding Byetta, ... LLY ) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... 2008 at 5:00 p.m. EDT to discuss the,recent FDA ... Lilly will be Donald Therasse, M.D., vice president of ...
... they spend billions out of pocket for what they do ... -- Uninsured Americans will spend $30 billion out of pocket ... in 2008, new research shows. , Uncompensated care is ... for by the uninsured or a health insurer. , In ...
... center for Tuesday, August 26, between 2:00 - 2:30 ... abortion., Two Catholic Priests, one Evangelical Pastor among ... Rescue Founder says:, "Obama,s pick of Biden is ... betrayal of his Faith will help mobilize Catholic,clergy and ...
... say bloodletting is the best available option for people ... -- Bloodletting is often dismissed as a primitive form ... the body of bad humors by draining the life-sustaining ... where bloodletting is still the preferred means of treatment. ...
... 25 Borrowing and sharing of,prescription medications is ... of nearly 7,500 women of reproductive age found ... of this population, according to a,report published online ... a,peer-reviewed journal published by Mary Ann Liebert, Inc. ...
... The U.S. Pharmacopeial (USP) Convention today announces a new ... physicians and others in avoiding medication errors that may ... sound alike. This "Drug Error Finder" is a searchable ... be involved in medication mix-ups in the U.S. health ...
Cached Medicine News:Health News:Lilly and Amylin Set Date and Time for Conference Call 2Health News:Uninsured Get Less Health Care Than Insured 2Health News:DNC 'Party Crashers:' Police Arrest 1 Pro-lifer at Black Caucus; Eject Operation Rescue Leader from DNC Interfaith Gathering at Colorado Convention Center 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 2Health News:For Rare Blood Disorder, Pumping Iron Is the Cure 3Health News:Trends in Prescription Medication Sharing Among Reproductive-Aged Women Reported in Journal of Women's Health 2Health News:USP announces new tool to help prevent medication mix-ups due to look alike/sound alike drug names 2
Shielding's Wrap-Around Apron is designed for front and back protection. This apron features extra wide shoulders distributing weight over a greater area to reduce fatigue....
Shielding's Velcro Adjustable Apron has two velcro flaps which aid in relieving weight off the shoulders. Its comfortable fit is attained by varying the position of flaps....
Upper arm protection...
This apron was designed by Pulse Medical-RCI for optimal protection. Your comfort is also a primary concern so a wide support belt and shoulder pads are standard. When properly fitted, an overlapping...
Medicine Products: